Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3121949 | 0.86 | MEN1 (0.52) | OPRM1TSHRGAATDP1KMT2A | |
| SCHEMBL3116314 | 0.85 | OPRM1 (0.50) | OPRM1TSHRGAATDP1KMT2A | |
| SCHEMBL3118687 | 0.85 | MEN1 (0.54) | OPRM1KDM4EALDH1A1TSHRGAA | |
| SCHEMBL3117177 | 0.84 | OPRM1 (0.52) | OPRM1GAATDP1KCNH2 | |
| SCHEMBL3112235 | 0.84 | OPRM1 (0.51) | OPRM1TSHRGAATDP1KMT2A | |
| SCHEMBL3117124 | 0.84 | ALDH1A1 (0.56) | OPRM1KDM4EALDH1A1TSHRGAA | |
| SCHEMBL4468382 | 0.84 | GAA (0.64) | KDM4EALDH1A1TSHRGAATDP1 | |
| SCHEMBL3113547 | 0.83 | SIGMAR1 (0.49) | OPRM1TSHRGAATDP1KMT2A | |
| SCHEMBL3122442 | 0.83 | SIGMAR1 (0.49) | OPRM1TSHRGAATDP1KMT2A | |
| SCHEMBL3116924 | 0.83 | SIGMAR1 (0.54) | OPRM1GAATDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179118-A1 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179118-A1 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179118-A1 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2060563-A1 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060563-A1 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179118-A1 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE | HRH2, HRH1, HRH4 | OPRM1 158/4885KDM4E 802/4885ALDH1A1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.